Evaluating patient experience and healthcare utilisation in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

被引:0
|
作者
Siu, Adrian [1 ,2 ]
Steffens, Daniel [1 ,2 ]
Ansari, Nabila [1 ,3 ]
Karunaratne, Sascha [1 ,2 ]
Solanki, Henna [1 ]
Ahmadi, Nima [1 ,3 ]
Solomon, Michael [1 ,2 ,3 ]
Koh, Cherry [1 ,2 ,3 ]
机构
[1] CO Royal Prince Alfred Hosp, Surg Outcomes Res Ctr SOuRCe, POB M157,Missenden Rd, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Sydney, NSW, Australia
[3] Royal Prince Alfred Hosp, Dept Colorectal Surg, Sydney, NSW, Australia
关键词
cytoreductive surgery; geographic disparity; healthcare equity; healthcare utilisation; hyperthermic intraperitoneal chemotherapy; patient experience; peritoneal malignancies; surgical oncology; HIPEC;
D O I
10.1071/AH24192
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective. Approximately 30% of Australians reside in rural communities, where accessing healthcare facilities can be challenging due to considerable distance. This can result in disparities in healthcare equity, subsequently increasing risk of adverse health outcomes, delayed diagnosis, and diminished quality of life. These geographical constraints may be exacerbated in advanced cancers for which treatment is available only at selected centres with appropriate expertise. The aim of this study was therefore to explore the impact of patient residence on experience and healthcare utilisation following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Methods. A retrospective study examined consecutive CRS and HIPEC patients at Royal Prince Alfred hospital from 2017 to 2022. Patients were stratified as metropolitan and regional based on their postcode. Demographics, experiential, and healthcare utilisation data were collected at multiple time points. Statistical analysis included chi-squared and T-tests. Results. Of the 317 participants, 228 (72%) were from metropolitan and 89 (28%) from regional areas. Regional patients tended to rate their hospital experience as 'very good' (P = 0.016). Metropolitan patients were more compliant with surgical follow-up (P < 0.001). No other differences were observed in patient characteristics, experience or healthcare utilisation. Conclusions. The geographical location of patients undergoing CRS and HIPEC for peritoneal malignancies at a major tertiary referral centre did not significantly influence their experience or healthcare utilisation outcomes. Future studies should evaluate long-term healthcare service utilisation or the ramifications of reduced follow-up on recurrence and survival, which will contribute to a deeper understanding of resource allocation in metropolitan and regional Australia, and illuminate its impact on clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection
    Esquivel, Jesus
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (01) : 72 - 78
  • [42] Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations
    Enomoto, Laura M.
    Shen, Perry
    Levine, Edward A.
    Votanopoulos, Konstantinos I.
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4231 - 4241
  • [43] Sclerosing Encapsulating Peritonitis in a Pediatric Patient Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Whitlock, Richard S.
    Malik, Tahir
    Smith, Valeria
    Mahajan, Priya
    Hayes-Jordan, Andrea
    Vasudevan, Sanjeev A.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (05) : E685 - E688
  • [44] Temperature management during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
    Ramirez, Maria F.
    Guerra-Londono, Juan Jose
    Owusu-Agyemang, Pascal
    Fournier, Keith
    Guerra-Londono, Carlos E.
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [45] Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery
    Mangieri, Christopher W.
    Moaven, Omeed
    Valenzuela, Cristian D.
    Erali, Richard A.
    Votanopoulos, Konstantinos, I
    Shen, Perry
    Levine, Edward A.
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 125 (04) : 703 - 711
  • [46] Fluid Administration and Morbidity in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Eng, O. S.
    Dumitra, S.
    O'Leary, M.
    Raoof, M.
    Wakabayashi, M.
    Dellinger, T. D.
    Han, E.
    Lee, S.
    Paz, I. B.
    Lee, B.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S78 - S78
  • [47] Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy, Part II: Implementation
    Dunn, Debra
    Ciccarelli, Eileen
    Moltzen, Nina
    AORN JOURNAL, 2019, 110 (06) : 606 - 625
  • [48] Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients
    Macri, Antonio
    Saladino, Edoardo
    Trimarchi, Giuseppe
    Bartolo, Vincenzo
    Rossitto, Maurizio
    Cannao, Antonio
    Rizzo, Antongiacomo
    Famulari, Ciro
    IN VIVO, 2011, 25 (04): : 687 - 690
  • [49] Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer
    Hall, JY
    Loggie, BW
    Shen, P
    Beamer, S
    Case, LD
    McQuellon, R
    Geisinger, KR
    Levine, EA
    JOURNAL OF GASTROINTESTINAL SURGERY, 2004, 8 (04) : 454 - 463
  • [50] Complications and Toxicities After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Canda, Aras Emre
    Sokmen, Selman
    Terzi, Cem
    Arslan, Cigdem
    Oztop, Ilhan
    Karabulut, Bulent
    Ozzeybek, Deniz
    Sarioglu, Sulen
    Fuzun, Mehmet
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (04) : 1082 - 1087